Study ID | Year | Sample size per experiment | Time point of measurement | Cell type | Type of bisphosphonate | Amount / concentration | ALP activity (3 days) | ALP activity (4 days) | ALP activity (7 days) | ALP activity (10 days) | ALP activity (14 days) | ALP activity (18 days) | ALP activity (21 days) | Coating specificaiton |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bigi et al. [40] | 2009 | 3 | 7, 14 days | MG-63 osteoblast like cells | Control | – |  |  | 2.17 ± 1.21 |  | 4.81 ± 0.27 |  |  | Hydroxyapatite |
Bigi et al. [40] | 2009 | 3 | 7, 14 days | MG-63 osteoblast like cells | Alendronate | 7 mM |  |  | 2.12 ± 0.20 |  | 4.72 ± 0.08 |  |  | Hydroxyapatite |
Bigi et al. [40] | 2009 | 3 | 7, 14 days | MG-63 osteoblast like cells | Alendronate | 28 mM |  |  | 2.29 ± 0.45 |  | 5.23 ± 0.14 |  |  | Hydroxyapatite |
Boanini et al. [41] | 2015 | 6 | 10, 21 days | MG-63 osteoblast like cells | Control | – |  |  |  | 0.82 ± 0.12 |  |  | 0.99 ± 0.12 | Strontium-substituted hydroxyapatite (SrHA) |
Boanini et al. [41] | 2015 | 6 | 10, 21 days | MG-63 osteoblast like cells | Zoledronat | Gradient composition C2 (SrHA and ZOLHA) |  |  |  | 1 ± 0.15 |  |  | 1.09 ± 0.08 | Strontium-substituted hydroxyapatite (SrHA) |
Boanini et al. [41] | 2015 | 6 | 10, 21 days | MG-63 osteoblast like cells | Zoledronat | Gradient composition C3 (SrHA and ZOLHA) |  |  |  | 0.79 ± 0.1 |  |  | 0.92 ± 0.08 | Strontium-substituted hydroxyapatite (SrHA) |
Boanini et al. [41] | 2015 | 6 | 10, 21 days | MG-63 osteoblast like cells | Zoledronat | Gradient composition C4 (SrHA and ZOLHA) |  |  |  | 0.75 ± 0,1 |  |  | 0.86 ± 0.16 | Strontium-substituted hydroxyapatite (SrHA) |
Boanini et al. [41] | 2015 | 6 | 10, 21 days | MG-63 osteoblast like cells | Zoledronat | ZOLHA |  |  |  | 0,80 ± 0.06 |  |  | 0.92 ± 0,15 | Strontium-substituted hydroxyapatite (SrHA) |
Boanini et al. [42] | 2015 | 6 | 14 days | Osteoblast derived from stem cells | Control | – |  |  |  |  | 10.6 ± 2.1 |  |  | Octacalcium phosphate |
Boanini et al. [42] | 2015 | 6 | 14 days | Osteoblast derived from stem cells | Alendronate | 8 mM |  |  |  |  | 16.3 ± 2.6 |  |  | Octacalcium phosphate |
Boanini et al. [42] | 2015 | 6 | 14 days | Osteoblast derived from stem cells | Alendronate | 20 mM |  |  |  |  | 9.63 ± 2.30 |  |  | Octacalcium phosphate |
Hu et al. [44] | 2013 | 5 | 14 days | MC3T3-E1 | Control | – |  |  |  |  | 0.41 ± 0.02 |  |  | Precoated hydroxyapatite (CaP) layer |
Hu et al. [44] | 2013 | 5 | 14 days | MC3T3-E1 | Alendronate | 0.2 mg/ml solution |  |  |  |  | 0.57 ± 0.04 |  |  | Precoated hydroxyapatite (CaP) layer |
Hu et al. [44] | 2013 | 5 | 14 days | MC3T3-E1 | Alendronate | 0.5 mg/ml solution |  |  |  |  | 0.59 ± 0.04 |  |  | Precoated hydroxyapatite (CaP) layer |
Hu et al. [44] | 2013 | 5 | 14 days | MC3T3-E1 | Alendronate | 1 mg/ml solution |  |  |  |  | 0.59 ± 0.63 |  |  | Precoated hydroxyapatite (CaP) layer |
Jeon et al [43] | 2019 | 5 | 3 days | MG-63 osteoblast like cells | Control | – | 1.11 ± 0.09 |  |  |  |  |  |  | UV treatment |
Jeon et al [43] | 2019 | 5 | 3 days | MG-63 osteoblast like cells | Alendronate | 10−3 M | 1.16 ± 0.17 |  |  |  |  |  |  | UV treatment |
Kim et al. [45] | 2013 | 5 | 7, 14, 21 days | MG-63 osteoblast like cells | Control | – |  |  | 1.12 ± 0.03 |  | 3.44 ± 0.14 |  | 4.01 ± 0.09 | Heparin-coated |
Kim et al. [45] | 2013 | 5 | 7, 14, 21 days | MG-63 osteoblast like cells | Alendronate | 1 mg/ml solution |  |  | 1.19 ± 0.04 |  | 5.29 ± 0.06 |  | 4.41 ± 0.12 | Heparin-coated |
Kim et al. [45] | 2013 | 5 | 7, 14, 21 days | MG-63 osteoblast like cells | Control | – |  |  | 1.31 ± 0.05 |  | 5.86 ± 0.23 |  | 4.65 ± 0.13 | BMP-2/Heparin-coated |
Kim et al. [45] | 2013 | 5 | 7, 14, 21 days | MG-63 osteoblast like cells | Alendronate | 1 mg/ml solution |  |  | 1.41 ± 0.04 |  | 6.65 ± 0.27 |  | 5.36 ± 0.13 | BMP-2/Heparin-coated |
Kim et al. [46] | 2017 | 3 | 7 days | MG-63 osteoblast like cells | Control | – |  |  | 1.49 ± 0.23 |  |  |  |  | without UV treatment |
Kim et al. [46] | 2017 | 3 | 7 days | MG-63 osteoblast like cells | Alendronate | 10−6 M |  |  | 4.08 ± 0.23 |  |  |  |  | without UV treatment |
Kim et al. [46] | 2017 | 3 | 7 days | MG-63 osteoblast like cells | Control | – |  |  | 3.49 ± 0.34 |  |  |  |  | with UV treatment |
Kim et al. [46] | 2017 | 3 | 7 days | MG-63 osteoblast like cells | Alendronate | 10−6 M |  |  | 6.22 ± 0.78 |  |  |  |  | with UV treatment |
Moon et al. [47] | 2011 | 3 | 7, 14, 21 days | MC3T3-E1 | Control | – |  |  | 2.56 ± 0.17 |  | 3.60 ± 0.06 |  | 3.48 ± 0.13 | Heparin-coated |
Moon et al. [47] | 2011 | 3 | 7, 14, 21 days | MC3T3-E1 | Alendronate | 1 mg |  |  | 3.55 ± 0.10 |  | 5.35 ± 0.17 |  | 4.36 ± 0.11 | Heparin-coated |
Moon et al. [47] | 2011 | 3 | 7, 14, 21 days | MC3T3-E1 | Alendronate | 5 mg |  |  | 4.24 ± 0.29 |  | 7.80 ± 0.21 |  | 5.35 ± 0.15 | Heparin-coated |
Mu et al. [48] | 2018 | 5 | 7 days | Osteoblasts from neonate rat calvaria | Control | – |  |  | 0.53 ± 0.05 |  |  |  |  | Hyaluronan |
Mu et al. [48] | 2018 | 5 | 7 days | Osteoblasts from neonate rat calvaria | Alendronate | 500 mg |  |  | 0.63 ± 0.06 |  |  |  |  | Hyaluronan |
Yoshinari et al. [49] | 2000 | 6 | 7 days | Osteoblastic cells from calvariae of Sprague-Dawley rats | Control | – |  |  | 51.7 ± 5.9 |  |  |  |  | Hydroxyapatite |
Yoshinari et al. [49] | 2000 | 6 | 7 days | Osteoblastic cells from calvariae of Sprague-Dawley rats | Pamidronate disodium | 10−2 M |  |  | 65.4 ± 9.7 |  |  |  |  | Hydroxyapatite |
Zheng et al. [50] | 2016 | 3 | 4,7,10,14,18 days | MC3T3-E1 | Control | – |  | 1.19 ± 0.15 | 1.81 ± 0.20 | 3.27 ± 0,38 | 3.30 ± 0.27 | 2.66 ± 0.25 |  | Plasma treated titanium |
Zheng et al. [50] | 2016 | 3 | 4,7,10,14,18 days | MC3T3-E1 | Alendronate | 2.5 mg/ml solution |  | 1.59 ± 0.13 | 2.36 ± 0.27 | 3.58 ± 0.20 | 3.66 ± 0.28 | 2.65 ± 0.25 |  | Plasma treated titanium |
Zheng et al. [50] | 2016 | 3 | 4,7,10,14,18 days | MC3T3-E1 | Control | – |  | 1.20 ± 0.16 | 1.95 ± 0,26 | 3.26 ± 0.16 | 3,3 ± 0.13 | 2.62 ± 0.36 |  | Plasma treated, silane-treated |
Zheng et al. [50] | 2016 | 3 | 4,7,10,14,18 days | MC3T3-E1 | Alendronate | 0.5 mg/ml solution |  | 1.52 ± 0.16 | 2.66 ± 0,16 | 3.93 ± 0.26 | 4.32 ± 0.30 | 3.18 ± 0.24 |  | Plasma treated, silane-treated |
Zheng et al. [50] | 2016 | 3 | 4,7,10,14,18 days | MC3T3-E1 | Alendronate | 1 mg/ml solution |  | 1.62 ± 0.12 | 3.39 ± 0,23 | 4.99 ± 0.28 | 3.70 ± 0.13 | 3.05 ± 0.14 |  | Plasma treated, silane-treated |